Summary A study was made of the intrinsic radiosensitivity of 140 biopsy and surgical specimens of malignant head and neck tumours of different histologies. Using a soft-agar clonogenic assay, the material was assessed for the ability to grow in culture (colony-forming efficiency; CFE) and inherent tumour radiosensitivity (surviving fraction at 2 Gy, SF2). The success rate for obtaining growth was 74% (104/140) with a mean CFE of 0.093% (median 0.031) and a range of 0.002-1.3%. SF2 was obtained for 88 of 140 specimens, representing a success rate of 63% with a mean SF2 of 0.48 (median 0.43) and a range of 0.10-1.00. There were no significant differences in radiosensitivity between different sites of the head and neck region. There were no significant relationships between SF2 and disease stage, nodal status, tumour grade, patient age, primary tumour growth pattern and CFE. The results were compared with those for other tumour types previously analysed with the same assay. The distribution of the SF2 values for the head and neck tumours was similar to that for 145 cervix carcinomas and there was no significant difference in mean radiosensitivity between the two tumour types. Also, there was no significant difference in radiosensitivity between head and neck tumours and either breast or colorectal cancers. However, a group of eight lymphomas was significantly more radiosensitive. These results confirm the feasibility of carrying out radiosensitivity measurements using a soft-agar clonogenic assay on head and neck tumours. In addition, the work has shown that radiosensitivity is independent of many clinical parameters and that the mean value is similar to that reported for cervix carcinomas.
The probability of achieving local control for patients undergoing radical radiotherapy has traditionally been said to depend on the 'Rs' of radiobiology: namely, repair of sublethal damage, reassortment of cells within the cell cycle, repopulation, reoxygenation and the inherent tumour radiosensitivity. Focusing on the last parameter the surviving fraction at 2 Gy (SF2) of human tumour cell lines has been shown to correlate with the radioresponsiveness of the tumour types from which they were derived (Deacon et al, 1984; Fertil and Malaise, 1985) . The predictive value of parameters of the low-dose region of radiation cell survival curves has also been confirmed by studies on experimental animal tumours (Bristow and Hill, 1990) and in mathematical modelling systems (Tucker and Thames, 1989) . These observations have given rise to a strong and growing interest in clinical radiobiological measurements of inherent radiosensitivity directly on human tumours to predict radiocurability (West, 1995) .
Few large prospective studies carried out on primary tumours have evaluated the predictive value of SF2 measurements for radiotherapy outcome. The cell adhesive matrix (CAM) assay has been used by two groups to evaluate tumour radiosensitivity in head and neck cancers. For patients treated with post-operative radiotherapy, SF2 was not predictive of treatment outcome (Brock et al, 1990 (Brock et al, , 1992 . However, in a study in which the majority of patients were treated with radiotherapy alone, tumour radiosensitivity was a significant prognostic factor (Girinsky et al, 1993 (Girinsky et al, , 1994 . Work using a soft-agar clonogenic assay to measure SF2 on cervical cancers undergoing radical radiotherapy has shown that tumour radiosensitivity is a highly significant and independent prognostic factor for both local control and overall survival (West et al, 1993 (West et al, , 1997 .
Neither the CAM nor the soft-agar clonogenic assays are suitable for routine clinical application. A period of 3 (CAM) or 4 (soft agar) weeks is required to generate data, and success rates in obtaining results are only around 70%. More rapid assays are being studied for their potential use in clinical studies: in particular the calorimetric microtitre (MTT) assay (Ramsay et al, 1992) , the micronucleus assay (Zolzer et al, 1995) , fluorescence in situ hybridization (Coco-Martin et al, 1994) and assays of DNA double-strand break repair (Zaffaroni et al, 1994; Schwartz et al, 1996) . Alongside this interest in evaluating the potential of rapid assays of tumour radiosensitivity, there is a need to show, within large prospective clinical studies, whether there is a future for radiosensitivity testing in cancers treated with radiotherapy alone or in combination with surgery. In view of the results obtained on carcinoma of the cervix using a soft-agar clonogenic assay, the following work was established using the same methods to assess the ability of SF2 measurements to predict outcome following radiotherapy for head and neck cancers. Clinically, prediction of radiocurability is of particular importance in head and neck oncology because of its high incidence, the fact that it is generally a locoregional disease, and that radiotherapy is used on the majority of patients. In addition, it is a disease for which radiotherapy and surgery can be competing modalities so that radiosensitivity testing could be used to determine the best primary (Spiessl et al, 1990) . No Media formulations (high antibiotic medium for tumour disaggregation and growth medium for tumour culture) and disaggregation methods have been described previously (Davidson et al, 1990 ).
The specimens were processed either fresh or after cryopreservation in liquid nitrogen. Before disaggregation the fresh specimens were stored in the dark at 4'C for 12-24 h in basal Eagle's medium gen,plus 20% fetal calf serum supplemented with 10 gtg ml-' I Photomicrogaphs of malignant (A) and fibroblast (B) colonies gentamycin, 10~t g ml-' amphotericin, 50 IU ml-' penicillin, in soft agar at x 100 and x 40 magnification respectively (original 50 Rtg ml-' streptomycin and 7 mm of Hepes buffer.
,ation) Single-cell suspensions were cultured in vitro using a soft-agar assay to obtain values for colony-forming efficiency (CFE) and SF,. Irradiation of the tumour single-cell suspensions was carried out using a caesium-137 or cobalt-60 source with a dose rate of 3.7 o -3 and 1-1.5 Gy min-' respectively. The cultures were grown in a 0 * _0gtr-humidified 5% CO2 and 5% 0°atmosphere at 37°C and fed°1 0 * weekly. After 4 weeks the colonies were stained for 24 h using p-1 * iodonitrotetrazolium violet before fixation in 4% formaldehyde.
;°Colonies with a diameter exceeding 60 gim, corresponding to more than 50 cells, were counted under a light microscope using an o0 ocular ruler or a videoplan image analysis system providing statistics of colony diameters as described previously (Davidson et Figure 3 The lack of correlation between tumour radiosensitivity (SF2) and colony-forming efficiency (CFE) for head and neck tumours (n = 88) test for differences in radiosensitivity between groups. A significance level of 0.05 was used throughout.
RESULTS

Colony morphology
As there have been studies that have reported the growth of fibroblasts in soft-agar clonogenic assays (Lawton et al, 1994; Stausbol-Gron et al, 1995) , care was taken to ensure that only colonies arising from malignant cells were scored. Colonies of two different morphological types were identified (Figure 1 ). The majority of the colonies were homogenous, tightly packed with round identical cells and with a colony diameter of approximately 60-200 gm. The malignant epithelial origin of these colonies was confirmed by staining with a low molecular weight cytokeratin marker (CAM 5.2). These colonies were counted as tumour cell colonies. A small and varying number (approximately 0-10%) of large, loose and star-shaped colonies was also seen. These colonies all stained positively with vimentin antibodies (Clone V 9) and were considered to represent fibroblast growth. Colonies with this appearance were not counted in the experiments. There were no difficulties in distinguishing between the two colony types according to their number and appearance.
Success rate A total of 104 out of 140 specimens (74%) were grown successfully with a mean ± standard deviation CFE of 0.093 ± 0.17% and a range of 0.0020-1.30%. Nineteen experiments became infected and 17 specimens failed to grow. The mean proportion of malignant cells in cell suspensions prepared from the biopsies was 56% with a wide range from 5% to 95%. The mean proportions of macrophages and inflammatory cells were 18% and 26%, ranging from 2% to 60% and 2% to 90% respectively. There were no significant relationships between CFE and the percentages of the different cell types in cell suspensions (P > 0.22).
SF2
SF2 values were obtained for 88 out of 140 specimens (63%) with a mean ± standard deviation of 0.48 + 0.025 and a range of 0.10-1.00. A cumulative frequency histogram of all 88 SF2 values is shown in Figure 2 . There was no significant relationship between tumour SF2 and CFE ( Figure 3 ) and patient age (P = 0.71). Information on tumour grade was available for 63 squamous cell carcinomas (Table 1 ). There were 25 poor, 30 moderate and eight well-differentiated tumours. There was no significant relationship between tumour grade and SF2(P > 0.49). For 41 of the squamous cell carcinomas, description of tumour growth pattern was available (Table 1) . There was no significant difference in the radiosensitivity of exophytic and ulcerative tumours (P = 0.58). Figure 2 ). There was no significant difference in the radiosensitivity of head and neck, cervix, colorectal and breast tumours. However, the lymphomas were significantly more radiosensitive than head and neck (P = 0.03), cervix (P = 0.02) and colorectal (P = 0.003) tumours. Using the Kruskal-Wallis test significant differences were seen in the radiosensitivity of different tumour types (P = 0.013). tests. However, intrinsic radiosensitivity expressed as parameters of the low-dose region of radiation cell survival curves is thought to be one of the most important and significant factors determining the response of a tumour to radiation treatment (Deacon et al, 1984; Fertil and Malaise, 1985; Tucker and Thames, 1989; Brock et al, 1990 Brock et al, , 1992 Davidson et al, 1990; West and Hendry 1992; West et al, 1993 West et al, , 1997 Girinsky et al, 1993 Girinsky et al, , 1994 .
DISCUSSION
In this study an examination has been made of the radiosensitivity of head and neck cancers using a clonogenic assay. We have shown that in vitro growth of tumours from the head and neck region can be achieved using a soft-agar assay. The culturing success rate was 74% and SF, was obtained for 63% of all patients biopsied. The latter figure is similar to the 60% success rate reported by Brock et al (1990) for primary head and neck carcinomas using the CAM assay. Girinsky et al (1993) reported a success rate for obtaining SF, values in head and neck cancers using the CAM assay of 75% when the cell yield was high enough to allow cell cultures to be set up. Using the same criteria we also obtained a success rate of 74% in obtaining SF, measurements.
Using a soft-agar assay, tumour cells grow as spherical colonies in an agar layer while the growth of cells that require anchorage to a solid substrate such as fibroblasts is inhibited. However, there have been reports recently that have shown that fibroblasts can grow in soft agar (Parkins and Steel, 1990; Lawton et al, 1994; Stausbol-Gron et al, 1995) . In the present study, fibroblast growth was not inhibited as a small number of large, star-shaped and vimentin-positive colonies was identified. No difficulties were found in the discrimination of such colonies and tumour. Unfortunately fibroblast colony numbers were too small to allow determination of fibroblast SF, and the colonies were all excluded in this study.
Other assays for measuring radiosensitivity are being investigated to increase both the assay time and success rate (see introduction) but none are suitable yet for routine clinical application. To date the strongest correlation between tumour radiosensitivity measurements and clinical outcome has been achieved using a soft-agar assay on cervix tumours treated with radical radiotherapy (West et al, 1993 (West et al, , 1997 . Girinisky et al (1993 Girinisky et al ( , 1994 ) also reported a significant but less strong relationship using the CAM assay in head and neck tumours treated predominantly with radiotherapy alone. It may be that by using a soft-agar assay a significant relationship might be found between tumour radiosensitivity and clinical outcome for cancers treated with post-operative radiotherapy. Therefore, despite the fact that Brock et al (1992) failed to show a relationship between tumour radiosensitivity measured using the CAM assay and clinical outcome in patients treated with radiotherapy plus surgery, there is interest in repeating his study using a soft-agar clonogenic assay. As soon as we have adequate followup, we will report on the correlation between SF, and outcome.
Using a soft-agar assay our mean value for the radiosensitivity of head and neck cancers was higher than those reported using the CAM assay (Brock et al, 1990; Girinsky et al, 1994) and this probably reflects differences between the two assays. The radiosensitivites of the head and neck cancers studied were variable (SF2 from 0.10 to 1.00). The latter observation supports the idea that a predictive assay based on tumour SF, measurements might be useful in head and neck cancers. In addition, we have found that the radiosensitivity of head and neck cancers is independent of many clinical parameters, i.e. stage, nodal status and patient age, and this confirms the findings of others (Brock et al, 1992; Girinsky et al, 1993 Girinsky et al, , 1994 . This study also confirmed the finding that there are no significant differences in mean radiosensitivity for tumours of different sites within the head and neck region (Girinsky et al, 1993; Pekkola-Heino et al, 1995) . The latter observation, however, is in contrast to a report by Brock et al (1992) , who found that oral cavity tumours were more radioresistant than carcinomas of the larynx, an observation that is consistent with clinical observations (Corv6 et al, 1994) . Primary tumour growth pattern scored as exophytic or ulcerating is clinically believed to represent different degrees of tumour oxygenation. We found no relationship between tumour radiosensitivity and growth pattern.
British Journal of Cancer (1998) 77 (12), [2371] [2372] [2373] [2374] [2375] We also found no relationship between tumour radiosensitivity and CFE, which confirms previous findings in a number of different tumour types (West et al, 1991; Girinsky et al, 1994) .
This study has also shown that head and neck and cervix tumours have similar radiosensitivity as reported by Girinsky et al ( 1993) using the CAM assay. Previous studies have suggested that there may be differences in the radiosensitivity ofprimary tumours (Rofstad et al, 1987; Brock et al, 1989) . However, for the first time, we report that there are significant differences in the radiosensitivity of different tumour types that can be measured in primary cultures without establishing cell lines.
The ultimate aim of this study is to correlate the radiosensitivity data with clinical outcome for a tumour type in which radiosensitivity could have a clear role to play in determining the optimum primary treatment (surgery/radiotherapy). This will require adequate follow-up, a minimum of 2 years, for all the patients studied and will be carried out in the future. However, as there is a lack of clinical measurements of radiosensitivity in primary human tumours, our preliminary data are presented here. This work has shown the feasibility of measuring head and neck cancer radiosensitivity using a soft-agar clonogenic assay and that using this assay the radiosensitivity is independent of many clinical features and is similar to that of cervix carcinomas. In addition, we have shown, in primary tumours, that cancers differ significantly in intrinsic radiosensitivity.
